Haematology and the Asian Patient: 51 Clinical Cases

Cover
Half Title
Title
Copyright
Contents
Foreword I
Foreword II
About the Authors
Acknowledgements
Haemostasis and Thrombosis
	Chapter 1 Von Willebrand Disease
		1.1 Clinical Scenario
		1.2 Laboratory Reports
		1.3 Questions
		1.4 Clinical Progress
		1.5 Von Willebrand Factor (VWF)
		1.6 Von Willebrand Disease (VWD)
		1.7 Diagnosis
		1.8 Differential Diagnosis
		1.9 Management
		1.10 Key Points
		Additional Readings
	Chapter 2 Severe Haemophilia
		2.1 Clinical Scenario
		2.2 Laboratory Reports
		2.3 Questions
		2.4 Haemophilia A
		2.5 Genetics
		2.6 Genetic Testing
		2.7 Differential Diagnosis
		2.8 Management
		2.9 Key Points
		Additional Readings
	Chapter 3 Factor VII Deficiency
		3.1 Clinical Scenario
		3.2 Laboratory Reports
		3.3 Questions
		3.4 Progress
			3.4.1 Factor VII
			3.4.2 Factor VII Deficiency
		3.5 Clinical Presentation
		3.6 Treatment
		3.7 Differential Diagnosis
		3.8 Key Points
		Additional Reading
	Chapter 4 Acquired Haemophilia
		4.1 Clinical Scenario
		4.2 Laboratory Reports
		4.3 Questions
		4.4 Clinical Progress
		4.5 Isolated APTT Prolongation
		4.6 Laboratory Confirmation of Acquired Factor VIII Inhibitor
		4.7 Causes of Acquired Factor VIII Inhibitor
		4.8 Treatment
		4.9 Key Points
		Additional Reading
	Chapter 5 Acquired Factor V Inhibitor
		5.1 Clinical Scenario
		5.2 Laboratory Reports
		5.3 Questions
		5.4 Clinical Progress
		5.5 Interpretation of Prolonged PT and APTT
			5.5.1 Acquired Factor V Inhibitor
		5.6 Key Points
		Additional Reading
	Chapter 6 Disseminated Intravascular Coagulopathy
		6.1 Clinical Scenario
		6.2 Laboratory Reports
		6.3 Questions
		6.4 Diagnosis
		6.5 Pathogenesis
		6.6 Management of DIC
		6.7 Key Points
		Additional Readings
	Chapter 7 Cancer-Related Thrombosis
		7.1 Clinical Scenario
		7.2 Laboratory Reports
		7.3 Questions
		7.4 Clinical Progress
		7.5 Pathogenesis
		7.6 Risk Factors of VTE
		7.7 Diagnosis of VTE
		7.8 Treatment
		7.9 Duration of Treatment
		7.10 Complications of VTE
		7.11 Key Points
		Additional Reading
Myeloid Malignancy
	Chapter 8 Acute Myeloid Leukaemia I
		8.1 Clinical Scenario
		8.2 Laboratory Reports
		8.3 Questions
		8.4 Clinical Progress
		8.5 Acute Myeloid Leukaemia—Diagnosis
		8.6 Clinical Presentation
		8.7 Prognostication
		8.8 MRD Monitoring
		8.9 Management of AML
		8.10 Key Points
		Additional Reading
	Chapter 9 Acute Myeloid Leukaemia II
		9.1 Clinical Scenario
		9.2 Laboratory Reports
		9.3 Questions
		9.4 Patient Progress
		9.5 Acute Myeloid Leukaemia (AML)
		9.6 Treatment of Acute Myeloid Leukaemia in the Elderly
		9.7 BCL2 Inhibitor
		9.8 Key Points
		Additional Readings
	Chapter 10 Myelodysplastic Syndrome
		10.1 Clinical Scenario
		10.2 Laboratory Reports
		10.3 Questions
		10.4 Progress
		10.5 Further Question
		10.6 Progress
		10.7 Myelodysplastic Syndrome
		10.8 Pathogenesis
		10.9 Differential Diagnosis
		10.10 Treatment
		10.11 Key Points
		Additional Reading
	Chapter 11 Chronic Myeloid Leukaemia
		11.1 Clinical Scenario
		11.2 Laboratory Reports
		11.3 Questions
		11.4 Clinical Progress
		11.5 Pathogenesis
		11.6 Clinical Presentation
		11.7 Laboratory Diagnosis
		11.8 Prognostic Factors
		11.9 Natural Disease Course
		11.10 Management of CML
		11.11 Monitoring Treatment Response to TKI
		11.12 Key Points
		Additional Reading
	Chapter 12 Essential Thrombocytosis
		12.1 Clinical Scenario
		12.2 Laboratory Reports
		12.3 Questions
		12.4 Clinical Progress
		12.5 Differential Diagnosis and Clinical Presentation
		12.6 Genetics of Essential Thrombocytosis
		12.7 Complications of Essential Thrombocytosis
		12.8 Prognosis
		12.9 Treatment
		12.10 Key Points
		Additional Readings
	Chapter 13 Polycythaemia Vera
		13.1 Clinical Scenario
		13.2 Laboratory Reports in 2013
		13.3 Questions
		13.4 Clinical Progress
		13.5 Laboratory Reports in 2021
		13.6 Clinical Features
		13.7 Prognosis
		13.8 Complications
		13.9 Management Plan
		13.10 Key Points
		Additional Reading
	Chapter 14 Primary Myelofibrosis
		14.1 Clinical Scenario
		14.2 Laboratory Reports
		14.3 Questions
		14.4 Clinical Progress
		14.5 Clinical Presentation
		14.6 Diagnosis
		14.7 Prognostication
		14.8 Treatment
		14.9 Key Points
		Additional Reading
	Chapter 15 Myeloid Neoplasm with Germline Predisposition
		15.1 Clinical Scenario
		15.2 Investigations and Patient Progress
		15.3 Questions
		15.4 Patient Progress
		15.5 Myeloid Neoplasm with Germline Predisposition
		15.6 Myeloid Neoplasms with Germline RUNX1 Mutation
		15.7 Key Points
		Additional Reading
	Chapter 16 Langerhans Cell Histiocytosis
		16.1 Clinical Scenario
		16.2 Questions
		16.3 Langerhans Cell Histiocytosis
		16.4 Other Histiocytosis
		16.5 Key Points
		Additional Readings
Lymphoid Malignancy
	Chapter 17 Diffuse Large B-Cell Lymphoma
		17.1 Clinical Scenario
		17.2 Diffuse Large B-Cell Lymphoma—Overview
		17.3 Aetiology
		17.4 Cell of Origin
		17.5 Molecular Landscape
		17.6 Clinical Presentation
		17.7 Management
		17.8 Prognostication
		17.9 Key Points
		Additional Readings
	Chapter 18 Waldenström Macroglobulinaemia
		18.1 Clinical Scenario
		18.2 Laboratory Reports
		18.3 Questions
		18.4 Clinical Progress
		18.5 Waldenström Macroglobulinaemia
		18.6 Clinical Manifestations
		18.7 Diagnosis
			18.7.1 Management of Waldenström Macroglobulinaemia
		18.8 Key Points
		Additional Readings
	Chapter 19 Chronic Lymphocytic Leukaemia
		19.1 Clinical Scenario
		19.2 Laboratory Reports
		19.3 Questions
		19.4 Clinical Progress
		19.5 Chronic Lymphocytic Leukaemia
		19.6 Diagnosis
		19.7 Prognostication
		19.8 Principle of Management
		19.9 Key Points
		Additional Readings
	Chapter 20 Hairy Cell Leukaemia
		20.1 Clinical Scenario
		20.2 Laboratory Reports
		20.3 Questions
		20.4 Clinical Progress
		20.5 Hairy Cell Leukaemia
		20.6 HCL Variant
		20.7 Key Points
		Additional Reading
	Chapter 21 Philadelphia Chromosome–Positive Acute Lymphoblastic Leukaemia
		21.1 Clinical Scenario
		21.2 Laboratory Reports
		21.3 Questions
		21.4 Patient Progress
		21.5 Precursor B-Cell ALL
		21.6 Philadelphia Chromosome–Positive ALL
		21.7 Treatment of Ph+ ALL
		21.8 Key Points
		Additional Readings
	Chapter 22 Natural Killer Cell Lymphoma
		22.1 Clinical Scenario
		22.2 Questions
		22.3 Clinical Progress
		22.4 NK/T-Cell Lymphoma
		22.5 Clinical Subtypes of NK/T-Cell Lymphoma
		22.6 Key Points
		Additional Reading
	Chapter 23 Mycosis Fungoides
		23.1 Clinical Scenario
		23.2 Questions
		23.3 Mycosis Fungoides
		23.4 Clinical Presentation
		23.5 Staging of Mycosis Fungoides
		23.6 Key Points
		Additional Readings
	Chapter 24 T-cell Prolymphocytic Leukaemia
		24.1 Clinical Scenario
		24.2 Laboratory Reports
		24.3 Questions
		24.4 Clinical Progress
		24.5 T-PLL
		24.6 Management
		24.7 Key Points
		Additional Reading
	Chapter 25 Hodgkin Lymphoma
		25.1 Clinical Scenario
		25.2 Questions
		25.3 Clinical Progress
		25.4 Differential Diagnoses
		25.5 Treatment and Prognosis
		25.6 Key Points
		Additional Reading
Plasma Cell Neoplasms
	Chapter 26 Amyloidosis
		26.1 Clinical Scenario
		26.2 Laboratory Reports
		26.3 Questions
		26.4 Diagnosis
		26.5 Amyloidosis
		26.6 Clinical Presentation
		26.7 Investigations
		26.8 Management
		26.9 Key Points
		Additional Reading
	Chapter 27 Multiple Myeloma
		27.1 Clinical Scenario
		27.2 Laboratory Reports
		27.3 Questions
		27.4 Progress
		27.5 Treatment Progress
		27.6 Multiple Myeloma
		27.7 Pathogenesis
		27.8 Clinical Features
		27.9 Investigations
		27.10 Prognostication
		27.11 Management Approach
		27.12 Key Points
		Additional Readings
	Chapter 28 POEMS Syndrome
		28.1 Clinical Scenario
		28.2 Laboratory Reports
		28.3 Questions
		28.4 POEMS Syndrome
		28.5 Patient Progress
		28.6 Treatment
		28.7 Key Points
		Additional Reading
Thalassaemia and Haemoglobin Disorders
	Chapter 29 Beta Thalassaemia Major
		29.1 Clinical Scenario
		29.2 Laboratory Reports
		29.3 Questions
		29.4 Clinical Progress
		29.5 Beta Thalassaemia
		29.6 Complications
		29.7 Management
		29.8 Key Points
		Additional Readings
	Chapter 30 Haemoglobin H Disease
		30.1 Clinical Scenario
		30.2 Laboratory Reports at Presentation
		30.3 Questions
		30.4 Clinical Progress
		30.5 Thalassaemia Syndromes
		30.6 Pathogenesis of Haemoglobin H Disease
		30.7 Clinical Presentations
		30.8 Laboratory Findings
		30.9 Differential Diagnosis
		30.10 Management
		30.11 Key Points
		Additional Readings
	Chapter 31 Sickle Cell Disease
		31.1 Clinical Scenario
		31.2 Laboratory Reports
		31.3 Questions
		31.4 Clinical Progress
		31.5 Sickle Cell Disease
		31.6 Pathogenesis
		31.7 Management
		31.8 Prevention of Sickling Crises
		31.9 Acute Sickling Crises and their Management
		31.10 Chronic Sickle Cell Diseases and their Management
		31.11 Key Points
		Additional Reading
	Chapter 32 Methaemoglobinaemia
		32.1 Clinical Scenario
		32.2 Laboratory Reports
		32.3 Questions
		32.4 Clinical Progress
		32.5 Laboratory Reports
		32.6 Normal Oxygen Transfer in Haemoglobin
		32.7 Drawback of Pulse Oximetry in Methaemoglobinaemia
		32.8 Saturation Gap
		32.9 Causes of Methaemoglobinaemia
		32.10 Clinical Presentation
		32.11 Treatment
		32.12 Key Points
		Additional Reading
Nutritional and Aplastic Anaemia
	Chapter 33 Aplastic Anaemia
		33.1 Clinical Scenario
		33.2 Laboratory Reports
		33.3 Questions
		33.4 Investigations
		33.5 Clinical Progress
		33.6 Aplastic Anaemia
		33.7 Pathophysiology
		33.8 Differential Diagnosis
		33.9 Management Approach
		33.10 Key Points
		Additional Readings
	Chapter 34 Iron Deficiency Anaemia
		34.1 Clinical Scenario
		34.2 Laboratory Results
		34.3 Questions
		34.4 Iron Metabolism
		34.5 Causes
		34.6 Symptoms
		34.7 Investigations
		34.8 Treatment
		34.9 Key Points
		Additional Readings
	Chapter 35 Vitamin B12 Deficiency Anaemia
		35.1 Clinical Scenario
		35.2 Laboratory Reports
		35.3 Questions
		35.4 Clinical Progress
		35.5 Further Laboratory Tests
		35.6 Sources of Vitamin B12 in the Body
		35.7 Dietary Vitamin B12 Absorption
		35.8 Cellular Function of Vitamin B12
		35.9 Clinical Manifestations
		35.10 Laboratory Features
		35.11 Bone Marrow Features
		35.12 Causes
		35.13 Pernicious Anaemia
		35.14 Treatment
		35.15 Key Points
		Additional Reading
Haemolytic Anaemia
	Chapter 36 Warm-Type Autoimmune Haemolytic Anaemia
		36.1 Clinical Scenario
		36.2 Laboratory Reports
		36.3 Questions
		36.4 Diagnosis
		36.5 Pathogenesis
		36.6 Differential Diagnosis
		36.7 Management
		36.8 Key Points
		Additional Readings
	Chapter 37 Cold Agglutinin Disease
		37.1 Clinical Scenario
		37.2 Laboratory Reports
		37.3 Questions
		37.4 Clinical Progress
		37.5 Cold Agglutinin Disease
		37.6 Pathogenesis of Haemolysis in CAD
		37.7 Cold Agglutinin Syndrome
		37.8 Investigations
		37.9 Treatment
		37.10 Key Points
		Additional Readings
	Chapter 38 G6PD Deficiency
		38.1 Clinical Scenario
		38.2 Laboratory Reports
		38.3 Questions
		38.4 Clinical Progress
		38.5 G6PD Physiology
		38.6 Genetics
		38.7 Haematological Effects
		38.8 Diagnosis
		38.9 Management
		38.10 Key Points
		Additional Readings
	Chapter 39 Hereditary Spherocytosis
		39.1 Clinical Scenario
		39.2 Laboratory Reports
		39.3 Questions
		39.4 Hereditary Spherocytosis
		39.5 Diagnosis
		39.6 Genetic Basis
		39.7 Management
		39.8 Key Points
		Additional Readings
	Chapter 40 Paravalvular Leak
		40.1 Clinical Scenario
		40.2 Laboratory Reports
		40.3 Questions
		40.4 Clinical Progress
		40.5 Cardiac Prosthesis-Related Haemolytic Anaemia
		40.6 Key Points
		Additional Reading
	Chapter 41 Paroxysmal Nocturnal Haemoglobinuria
		41.1 Clinical Scenario
		41.2 Laboratory Reports
		41.3 Questions
		41.4 Clinical Progress
		41.5 Pathogenesis
		41.6 Clinical Manifestations
		41.7 Diagnosis
		41.8 Treatment
		41.9 Key Points
		Additional Readings
	Chapter 42 Thrombotic Thrombocytopenic Purpura
		42.1 Clinical Scenario
		42.2 Laboratory Reports
		42.3 Questions
		42.4 Clinical Progress
		42.5 Differential Diagnosis of Thrombotic Microangiopathy
		42.6 Pathogenesis
		42.7 Clinical Features
		42.8 Causes
		42.9 Investigations
		42.10 Management Approach
		42.11 Key Points
		Additional Readings
	Chapter 43 Atypical Haemolytic Uraemic Syndrome
		43.1 Clinical Scenario
		43.2 Laboratory Reports
			43.2.1 Haematology
			43.2.2 Biochemistry
		43.3 Questions
		43.4 Clinical Progress
		43.5 Thrombotic Microangiopathy During Pregnancy
		43.6 Haemolytic Uraemic Syndrome
		43.7 Classification
		43.8 Diagnosis
		43.9 Management
		43.10 Key Points
		Additional Reading
Thrombocytopenia
	Chapter 44 Immune Thrombocytopenia
		44.1 Clinical Scenario
		44.2 Laboratory Reports
		44.3 Questions
		44.4 Clinical Progress
		44.5 Clinical Features
		44.6 Pathogenesis
		44.7 Diagnosis
		44.8 Management
		44.9 Key Points
		Additional Readings
	Chapter 45 Hereditary Macrothrombocytopenia
		45.1 Clinical Scenario
		45.2 Laboratory Reports
		45.3 Questions
		45.4 Clinical Progress
		45.5 Hereditary Macrothrombocytopenia—Clinical Spectrum
		45.6 Diagnosis
		45.7 Clinical Relevance
		45.8 Key Points
		Additional Readings
Miscellaneous Conditions
	Chapter 46 Castleman Disease
		46.1 Clinical Scenario
		46.2 Laboratory Reports
		46.3 Questions
		46.4 Clinical Progress
		46.5 Castleman Disease
		46.6 Diagnosis
		46.7 Management
		46.8 Key Points
		Additional Readings
	Chapter 47 Haemophagocytic Lymphohistiocytosis
		47.1 Clinical Scenario
		47.2 Laboratory Reports
			47.2.1 Haematology
			47.2.2 Biochemistry
		47.3 Clinical Progress
		47.4 Questions
		47.5 Diagnosis
		47.6 Pathophysiology
		47.7 Clinical Presentation
		47.8 Diagnosis
		47.9 Treatment
		47.10 Key Points
		Additional Readings
	Chapter 48 Hypereosinophilia
		48.1 Clinical Scenario
		48.2 Laboratory Reports
		48.3 Questions
		48.4 Clinical Progress
		48.5 Eosinophilia
		48.6 Hypereosinophilic Syndrome
		48.7 Clinical Presentation
		48.8 Management
		48.9 Key Points
		Additional Readings
	Chapter 49 IgG4–Related Disease
		49.1 Clinical Scenario
		49.2 Laboratory Reports
		49.3 Questions
		49.4 IgG4–Related Disease
		49.5 Investigations
		49.6 Differential Diagnoses
		49.7 Treatment
		49.8 Key Points
		Additional Reading
	Chapter 50 Lymphadenopathy and Hypergammaglobulinaemia
		50.1 Clinical Scenario
		50.2 Laboratory Reports
		50.3 Questions
		50.4 Causes
		50.5 Investigations
		50.6 Clinical Progress
		50.7 Human Immunodeficiency Virus (HIV) Infection
		50.8 Key Points
		Additional Reading
	Chapter 51 Paraneoplastic Pemphigus
		51.1 Clinical Scenario
		51.2 Laboratory Reports
		51.3 Questions
		51.4 Clinical Progress
		51.5 Paraneoplastic Pemphigus
		51.6 Pathogenesis
		51.7 Treatment
		51.8 Key Points
		Additional Readings
Index